76.21

0.74% 0.56

Pre-market: 76.03 -0.18 -0.24%

Astrazeneca PLC (AZN)

Overview News Price History Option Chain Why AZN Down? Discussions Forecast Stock Split Dividend History

Astrazeneca PLC stock is traded at $76.21, with a volume of 11.13M. It is up +0.74% in the last 24 hours and up +7.70% over the past month. AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.

Previous Close:

$75.65

Open:

$75.83

24h Volume:

11.13M

Relative Volume:

2.14

Market Cap:

$236.27B

Revenue:

$54.07B

Net Income/Loss:

$7.04B

P/E Ratio:

33.80

EPS:

2.255

Net Cash Flow:

$7.28B

1W Performance:

+2.68%

1M Performance:

+7.70%

6M Performance:

-13.02%

1Y Performance:

+18.78%

1-Day Range:

$75.30

$76.26

1-Week Range:

$74.19

$76.26

52-Week Range:

$62.75

$87.67

Astrazeneca PLC Stock (AZN) Company Profile

Name

Astrazeneca PLC

Sector

Healthcare (1169)

Industry

Drug Manufacturers - Major (1)

Phone

44 20 3749 5000

Address

1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge

Employee

61,100

Twitter

@AstraZeneca

Next Earnings Date

2024-11-12

Latest SEC Filings

AZN's Discussions on Twitter

Compare AZN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AZN Astrazeneca PLC	76.21	236.27B	54.07B	7.04B	7.28B	2.255

Astrazeneca PLC Stock (AZN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-13-25	Upgrade	UBS	Neutral → Buy
Feb-12-25	Initiated	Morgan Stanley	Overweight
Nov-20-24	Upgrade	UBS	Sell → Neutral
Nov-06-24	Upgrade	Deutsche Bank	Sell → Hold
Sep-13-24	Downgrade	Deutsche Bank	Hold → Sell
May-30-24	Initiated	Goldman	Buy
Apr-16-24	Upgrade	Deutsche Bank	Sell → Hold
Feb-08-24	Downgrade	Deutsche Bank	Hold → Sell
Jan-23-24	Initiated	Morgan Stanley	Overweight
Jan-16-24	Resumed	UBS	Sell
Jan-03-24	Downgrade	Jefferies	Buy → Hold
Dec-18-23	Initiated	HSBC Securities	Buy
Sep-25-23	Upgrade	Jefferies	Hold → Buy
Jul-14-23	Initiated	HSBC Securities	Buy
Jul-12-23	Upgrade	UBS	Neutral → Buy
Jul-05-23	Downgrade	Deutsche Bank	Buy → Hold
Apr-11-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jan-05-23	Initiated	BMO Capital Markets	Outperform
Sep-15-22	Downgrade	Credit Suisse	Outperform → Neutral
Sep-07-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Aug-29-22	Upgrade	Argus	Hold → Buy
Jun-14-22	Downgrade	UBS	Buy → Neutral
Feb-11-22	Upgrade	DZ Bank	Sell → Hold
Dec-07-21	Downgrade	Jefferies	Buy → Hold
Aug-12-21	Resumed	JP Morgan	Overweight
Apr-12-21	Downgrade	Argus	Buy → Hold
Mar-16-21	Upgrade	Jefferies	Hold → Buy
Feb-25-21	Upgrade	UBS	Neutral → Buy
Jan-15-21	Initiated	Deutsche Bank	Buy
Dec-07-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Nov-30-20	Upgrade	UBS	Sell → Neutral
Nov-11-20	Upgrade	HSBC Securities	Reduce → Hold
Sep-29-20	Initiated	Berenberg	Buy
Nov-22-19	Initiated	SVB Leerink	Outperform
Oct-25-19	Upgrade	Liberum	Hold → Buy
Apr-02-19	Downgrade	UBS	Neutral → Sell
Feb-05-19	Initiated	Exane BNP Paribas	Outperform
Jan-25-19	Upgrade	Shore Capital	Hold → Buy
Dec-11-18	Resumed	Jefferies	Hold
Oct-09-18	Initiated	Guggenheim	Buy
Aug-16-18	Downgrade	Jefferies	Buy → Hold
Mar-19-18	Upgrade	Jefferies	Hold → Buy
Feb-06-18	Reiterated	Leerink Partners	Mkt Perform
Feb-05-18	Reiterated	Bernstein	Outperform
Jan-18-18	Reiterated	Leerink Partners	Mkt Perform
Dec-29-17	Upgrade	JP Morgan	Neutral → Overweight
Oct-16-17	Upgrade	Credit Suisse	Neutral → Outperform
Sep-25-17	Upgrade	Exane BNP Paribas	Neutral → Outperform
Sep-22-17	Upgrade	Bernstein	Mkt Perform → Outperform

View All

Astrazeneca PLC Stock (AZN) Latest News

04:31 AM

AstraZeneca: CHMP recommends Imfinzi in lung cancer -March 03, 2025 at 04:31 am EST - Marketscreener.com

04:31 AM

04:08 AM

AstraZeneca: Tezspire effective against rhino-sinusitis -March 03, 2025 at 04:08 am EST - Marketscreener.com

04:08 AM

03:38 AM

AstraZeneca's Imfinzi gets recommended for fresh EU approval - ShareCast

03:38 AM

Mar 02, 2025

AZN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that AstraZeneca PLC Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Mar 02, 2025

Is AstraZeneca PLC (AZN) The Best Immunology Stock To Buy Now? - Insider Monkey

Mar 02, 2025

AstraZeneca, Amgen Drug Exhibits Treatment Signs in Nasal Polyps Trials -March 02, 2025 at 06:30 am EST - Marketscreener.com

Mar 02, 2025

Mar 01, 2025

Is AstraZeneca PLC (AZN) the Best Weight Loss Drug Stock to Buy According to Analysts? - Insider Monkey

Mar 01, 2025

Flputnam Investment Management Co. Has $19.24 Million Position in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat

Mar 01, 2025

Dynasty Wealth Management LLC Purchases Shares of 12,012 AstraZeneca PLC (NASDAQ:AZN) - MarketBeat

Mar 01, 2025

Oppenheimer Asset Management Inc. Purchases 10,653 Shares of AstraZeneca PLC (NASDAQ:AZN) - MarketBeat

Mar 01, 2025

Proficio Capital Partners LLC Buys 697,801 Shares of AstraZeneca PLC (NASDAQ:AZN) - MarketBeat

Mar 01, 2025

NewEdge Wealth LLC Raises Stake in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat

Mar 01, 2025

JFG Wealth Management LLC Purchases Shares of 3,506 AstraZeneca PLC (NASDAQ:AZN) - MarketBeat

Mar 01, 2025

Feb 28, 2025

AstraZeneca PLC (NASDAQ:AZN) Shares Bought by Altrius Capital Management Inc - MarketBeat

Feb 28, 2025

AstraZeneca’s Enhertu gains CHMP nod for breast cancer - Investing.com India

Feb 28, 2025

EU backs AstraZeneca, Daiichi's Enhertu for breast cancer treatment post endocrine therapy - Reuters

Feb 28, 2025

AstraZeneca: Enhertu recommended for approval in the EU -February 28, 2025 at 09:48 am EST - Marketscreener.com

Feb 28, 2025

Shareholder Rights Advocates at Levi & Korsinsky Investigate AstraZeneca PLC (AZN) Regarding Possible Securities Fraud Violations - ACCESS Newswire

Feb 28, 2025

Whipplewood Advisors LLC Purchases New Holdings in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat

Feb 28, 2025

AstraZeneca Partnership Opens UK Biomethane Plant for Clean Energy -February 28, 2025 at 12:48 am EST - Marketscreener.com

Feb 28, 2025

Feb 27, 2025

SERD-ified progress: Astrazeneca, others advance in breast cancer - BioWorld Online

Feb 27, 2025

AstraZeneca opens biomethane plant in UK to cut emissions - Reuters

Feb 27, 2025

GSK abandons diversity targets following Trump pressure - Reuters

Feb 27, 2025

Feb 26, 2025

Non-Small Cell Lung Cancer Market Set for Significant Growth Across the 7MM During the Study Period (2025-2034) Due to the Rising Novel Therapeutic Options | DelveInsight - GlobeNewswire Inc.

Feb 26, 2025

AstraZeneca’s Oral SERD Is First To Succeed In Frontline Breast Cancer - Insights

Feb 26, 2025

AstraZeneca’s next breast cancer drug; Madrigal’s accelerating MASH launch - BioPharma Dive

Feb 26, 2025